This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed ...

Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer ... and recent challenges in the capital markets have required ...

Ratings for Pfizer PFE were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...